GAM
CRL icon

Grandview Asset Management’s Charles River Laboratories CRL Stock Holding History

Grandview Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$29K – 176
2021
Q1 		$29K Buy
+100
New +$27.8K 0.02% 248
2019
Q4 		– Sell
-1,589
Closed -$204K – 90
2019
Q3 		$204K Hold
1,589
– – 0.18% 98
2019
Q2 		$225K Sell
1,589
-325
-17% -$44.1K 0.21% 95
2019
Q1 		$278K Buy
+1,914
New +$251K 0.26% 81

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Grandview Asset Management's CRL Position: Q2 2021 in Review

Grandview Asset Management sold out of Charles River Laboratories (CRL) in Q2 2021, closing a stake of 100 shares — an estimated $29K sold.

Grandview Asset Management first reported a position in CRL in Q1 2019 and held it in 4 quarters. The position peaked at $278K in Q1 2019. 639 funds tracked by Wall St. Rank hold CRL as of Q2 2021.

  • Grandview Asset Management reported no remaining Charles River Laboratories position as of Q2 2021 after selling out during the quarter.
  • Grandview Asset Management sold 100 Charles River Laboratories shares in Q2 2021, an estimated $29K.
  • Grandview Asset Management first reported a position in Charles River Laboratories in Q1 2019 and held it in 4 quarters.
  • Grandview Asset Management's Charles River Laboratories position peaked at $278K in Q1 2019.
  • 639 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2021.

Based on Grandview Asset Management's 13F filing for Q2 2021, filed 21 Jul 2021.